5-Amino-1MQ vs Sermorelin

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

5-Amino-1MQSermorelin
CategoryPeptidesPeptides
Standard DoseResearch indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.
TimingMorning dosing preferred. Can be taken with or without food.Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.
Cycle Duration8-12 week cycles.12-24 week cycles. Some protocols use continuous treatment.
Evidence Levelanimal_plus_anecdotalstrong_human
A

5-Amino-1MQ

Peptides

Mechanism

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Standard Dosing

Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Timing

Morning dosing preferred. Can be taken with or without food.

Cycle Duration

8-12 week cycles.

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Best Stacking Partners

MOTS-cAOD-9604TesofensineSemaglutide
B

Sermorelin

Peptides

Mechanism

Sermorelin is a synthetic 29-amino acid peptide representing the biologically active fragment of GHRH (amino acids 1-29) with full functional activity. It activates GHRH receptors on pituitary somatotrophs, stimulating cAMP production via Gs protein/adenylate cyclase and MAP kinase pathways. Due to the interactive effects of sermorelin and endogenous somatostatin, GH release is episodic rather than continuous. Sermorelin also stimulates pituitary gene transcription of GH mRNA, increasing and preserving pituitary GH reserve.

Standard Dosing

Research indicates 200-300 mcg administered once daily at bedtime via subcutaneous injection.

Timing

Bedtime administration (aligns with natural nocturnal GH release). On empty stomach.

Cycle Duration

12-24 week cycles. Some protocols use continuous treatment.

Side Effects

  • Injection site reactions
  • Facial flushing
  • Headache
  • Dizziness
  • Transient taste changes

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →